Exelixis, Inc. (EXEL) is listed on NASDAQ in Biotech Stocks. It is $54.45, -1.47%, with a $13.5B market cap. RSI is 50.2, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 50.2 Neutral
Market Cap $13.5B
Volume 1.6M
Fundamentals — 10-Q Q2 2026
Revenue $1.2B
Net Income $422.5M
EPS $1.60
Gross Margin 96.7%
Operating Margin 40.3%
Net Margin 34.1%
P/E Ratio 34.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Beckerle Mary C | Director | Sell | 9,812 | $53.66 | $526,512 | 2026 Aug 10 |
| Wyszomierski Jack L | Director | Sell | 3,925 | $50.55 | $198,409 | 2026 Jun 1 |
| Eckhardt Sue Gail | Director | Sell | 9,812 | $50.14 | $491,974 | 2026 Jun 1 |
| Aftab Dana | EVP, Research and Development | Sell | 43,451 | $50.35 | $2.2M | 2026 May 26 |
| Haley Patrick J. | EVP, Commercial | Sell | 32,110 | $49.81 | $1.6M | 2026 May 20 |
| Senner Christopher J. | EVP and CFO | Sell | 34,901 | $50.00 | $1.7M | 2026 May 18 |
| Hefti Brenda | SVP and General Counsel | Sell | 6,625 | $50.21 | $332,641 | 2026 May 18 |
| Beckerle Mary C | Director | Sell | 7,712 | $48.45 | $373,646 | 2026 May 7 |
| Freire Maria C | Director | Sell | 20,634 | $46.00 | $949,164 | 2026 May 7 |
| Poste George | Director | Sell | 60,000 | $45.71 | $2.7M | 2026 May 7 |
| Aftab Dana | EVP, Research and Development | Sell | 47,918 | $44.50 | $2.1M | 2026 Feb 24 |
| Aftab Dana | EVP, Research and Development | Sell | 29,873 | $44.35 | $1.3M | 2026 Feb 19 |
| Johnson David Edward | Director | Buy | 27,532 | $43.12 | $1.2M | 2025 Nov 25 |
| Haley Patrick J. | EVP, Commercial | Sell | 72,230 | $42.18 | $3.0M | 2025 Nov 21 |
| Papadopoulos Stelios | Director | Sell | 100,000 | $43.55 | $4.4M | 2025 Nov 12 |
| Aftab Dana | EVP, Research and Development | Sell | 48,383 | $42.50 | $2.1M | 2025 Nov 11 |
| Beckerle Mary C | Director | Sell | 24,622 | $41.93 | $1.0M | 2025 Nov 11 |
| Wyszomierski Jack L | Director | Sell | 7,535 | $43.09 | $324,683 | 2025 Jun 3 |
| Eckhardt Sue Gail | Director | Sell | 18,838 | $42.74 | $805,140 | 2025 Jun 2 |
| Heyman Tomas J. | Director | Sell | 4,544 | $44.29 | $201,254 | 2025 May 21 |
Other Biotech Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $137.93 | 63.6 | $55.1B |
| | $432.33 | 66.2 | $233.7B |
| | $145.64 | 60.3 | $180.6B |
| | $118.23 | 51.7 | $9.8B |
| | $8.05 | 54.2 | $8.5B |
| | $176.24 | 62.2 | $9.9B |
| | $43.12 | 53.6 | -- |
Take EXEL further
- Browse Biotech Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put EXEL in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Exelixis, Inc. next reports.
Set alerts on EXEL
Get notified when Exelixis, Inc. hits your price targets or technical conditions are met.
Get Started Free